You’re headed to a secure site to finish your request

There is a $24.95 fee for an independent telehealth provider to review your request. It works much like a typical copay at a doctor’s office.

Have your insurance card handy. It takes about 5 minutes.

30
Continue to secure site Remind me Later
Get a reminder

By submitting this form, I agree that Guardant Health, Inc. and its affiliates (“GH”) and representatives may email, call, and / or text me with marketing messages about GH products and services, as well as send me messages related to any existing patient orders I have made, at any phone number I provide, including a wireless number, using prerecorded calls or automated technology. I understand that my consent is not required to make any purchase. I understand that if I do submit this form, I may unsubscribe within marketing emails or opt-out of text messages at any time by replying “STOP.” Standard text message and data rates may apply.

By submitting this form, I further understand and acknowledge that all information provided is subject to GH’s Privacy Policy available at https://guardanthealth.com/contact/privacy-policy/

Please check to agree

You’ve successfully signed up!
We’re excited to keep you informed.

Oops!
Please check your information and try again.

Retry

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is intended for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stages II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not intended for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Patient Fact Sheet (opens in a new window) for complete product information about the Shield test including full safety information.


Shield is available by Rx only.

*Medicare Advantage patients may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan.

  1. References:
  2. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973983. doi:10.1056/NEJMoa2304714 2. Shield™ Provider Brochure. Redwood City, CA: Guardant Health, 2024